Communicating genetic risk: Pros, cons, and counsel

Oncologist

Volumn 5, Issue 2, 2000, Pages 152-161

  Penson, Richard T ^a   Seiden, Michael V ^a   Shannon, Kristen M ^a   Lubratovich, Marcie L ^a   Roche, Maria ^a   Chabner, Bruce A ^a   Lynch Jr , Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

BRCA 1; BRCA 2; Breast cancer; Genetic counseling; Ovarian cancer; Psychosocial

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CASE REPORT; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

EID: 0034100312     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-2-152     Document Type: Article

References (48)

1. Hahn WC, Counter CM, Lundberg AS et al. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-468.
2. Broca P. Traite des Tumeurs, Paris: Asselin, 1866.
3. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820.
4. Harris H, Miller OJ, Klein G et al. Suppression of malignancy by cell fusion. Nature 1969:223:363-368.
5. Hall JM, Lee MNK, Newman B et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990:250:1684.
6. Miki Y, Swensen J, Shattuck-Edens D et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
7. Wooster R, Bignell G, Lancaster J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792.
8. Zhong Q, Chen CF, Li S et al. Association of BRCA1 with the hRad50-hMRe11-p95 complex and the DNA damage response. Science 1999;285:747-750.
9. Cortez D, Wang Y, Qin J et al. Requirement of ATM-dependent phosphorylation of BRCA1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-1166.
10. Verhoog LC, Brekelmans CT, Seynaeve C et al. Survival in hereditary breast cancer associated with germline mutations of BRCA2. J Clin Oncol 1999;17:3396-3402.
11. Struewing JP, Hartge P, Wacholder S et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408.
12. Gross PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol 1998;16:338-347.
13. Gofman JW. Mammography: an individual's estimated risk that the examination itself will cause radiation-induced breast cancer. In: Preventing Breast Cancer: The Story of a Major, Proven. Preventable Cause of This Disease. Second Edition. San Francisco: Committee for Nuclear Responsibility, Inc. C.N.R. Book Division, 1996:172-181.
14. Smith TE, Harrold EV, Matloff ET et al. BRCA1/2 status, family history and ipsilateral breast tumor relapse following conservative surgery and radiation therapy. Proc Am Soc Clin Oncol 1999:2413a.
15. Simmonds P, Eccles D, Goddard J et al. Is breast conservation appropriate for women with hereditary breast cancer? Proc Am Soc Clin Oncol 1999;18:2363a.
16. Turner BC, Harrold E, Matloff E et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 1999;10:3017-3024.
17. Sakorafas GH, Tsiotuo AG. Genetic predisposition to breast cancer: a surgical perspective. Br J Surg 2000;87:149-162.
18. Berchuck A, Heron KA, Carney ME et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res 1998;4:2433-2437.
19. Baldwin RL, Trang HT, Elizabeta N et al. BRCA1 promoter hypermethylation: a mechanism of gene inactivation in sporadic ovarian carcinoma. Prog Soc Gynecol Oncol 2000:Abstract 27.
20. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993;71:677-685.
21. Langston AA, Malone KE, Thompson JD et al. BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 1996;334:137-142.
22. Fitzgerald MG, MacDonald DJ, Krainer M et al. Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med 1996;334:143-149.
23. Wagner TM, Moslinger RA, Muhr D et al. BRCA1 related breast cancer in Austrian breast and ovarian cancer families: specific BRCA1 mutations and pathological characteristics. Int J Cancer 1998;77:354-360.
24. Couch FJ, Deshano ML, Blackwood MA et al. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 1997;336:1409-1415.
25. Berry DA, Parmigiani G, Sanchez J et al. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 1997:89:227-238.
26. Parmigiani G, Berry DA, Aguilar O. Determining carrier probabilites for breast cancer susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 1998;62:145-158.
27. Tian H, Jaquins-Gerstl A, Munro N et al. Single-strand conformation polymorphism analysis by capillary and microchip electrophoresis: a fast, simple method for detection of common mutations in BRCA1 and BRCA2. Genomics 2000;63:25-34.
28. Mogilner A, Otten M, Cunningham JD et al. Awareness and attitudes concerning BRCA gene testing. Ann Surg Oncol 1998;5:607-612.
29. McKinnon WC, Baty BJ, Bennett RL et al. Predisposition genetic testing for late-onset disorders in adults: a position paper of the National Society of Genetic Counselors. JAMA 1997;278:1217-1220.
30. Haber DA. Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. J Clin Oncol 1999;17:3367-3370.
31. Schneider KA. Genetic counseling for BRCA1/BRCA2 testing. Genetic Testing 1997;1:91-98.
32. Geller G, Botkin JR, Green MJ et al. Genetic testing for susceptibility to adult-onset cancer: the process and content of informed consent. JAMA 1997;277:1467-1473.
33. Am Soc Clin Oncol Special Article: Recommended breast cancer surveillance guidelines. J Clin Oncol 1997;15:2149-2156.
34. Lawson K, Wiggins S, Green T et al. Adverse psychological events occurring in the first year after predictive testing for Huntington's disease. The Canadian collaborative study predictive testing. J Med Genet 1996;33:856-862.
35. Fallowfield LJ, Hall A, Maguire GP et al. Psychological outcomes of different treatment policies in women with early breast cancer outside a clinical trial. Br Med J 1990;301:575-580.
36. Thirlaway K, Fallowfield L, Nunnerley H et al. Anxiety in women "at risk" of developing breast cancer. Br J Cancer 1996;73:1422-1424.
37. Francis V, Korsch B, Morris M. Gaps in doctor-patient communication. N Engl J Med 1969;280:535-538.
38. Donovan JL, Blake DR. Qualitative study of interpretation of reassurance among patients attending rheumatology clinics: "just a touch of arthritis, doctor?" Br Med J 2000;320:541-544.
39. Burke W, Daly M, Garber J et al. Recommendations for follow-up care of individuals with inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA. 1997;277:997-1003.
40. Fletcher SW, Black W, Harris R et al. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993;85:1644-1656.
41. Antman K, Shea S. Screening mammography under age 50. JAMA 1999;281:1470-1472.
42. Fletcher SW. Confusion about breast cancer screening [Letter]. N Engl J Med 1997;337:1850.
43. NIH Consensus Conference. Ovarian cancer: screening, treatment, and follow-up. JAMA 1995;273:491-497.
44. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-1210.
45. Schrag D, Kuntz KM, Garber JE et al. Decision analysis: effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 and BRCA2 mutations. N Engl J Med 1997;336:1465-1471.
46. Fisher B, Constantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
47. Cummings SR, Eckert S, Krueger KA et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial - Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-2197.
48. Adams D. The Hitchhiker's Guide to the Galaxy. Ballantine Books.